Combination nivolumab- and cabiralizumab-associated acute bilateral anterior and posterior scleritis and anterior uveitis

John A Gonzales; Jessica Shantha; Nisha R Acharya

doi:10.1016/j.ajoc.2018.02.005

Combination nivolumab- and cabiralizumab-associated acute bilateral anterior and posterior scleritis and anterior uveitis

Am J Ophthalmol Case Rep. 2018 Feb 8:10:117-118. doi: 10.1016/j.ajoc.2018.02.005. eCollection 2018 Jun.

Authors

John A Gonzales^{1

2}, Jessica Shantha^{1

2}, Nisha R Acharya^{1

2}

Affiliations

¹ F.I. Proctor Foundation, University of California, San Francisco, United States.
² Department of Ophthalmology, University of California, San Francisco, United States.

Abstract

Purpose: To report on a case of uveitis and scleritis resulting as an immune-mediated side effect of cancer immunotherapy with nivolumab and cabiralizumab.

Observations: Bilateral anterior nongranulomatous anterior uveitis and bilateral diffuse anterior and posterior scleritis occurred following the use of combination cancer immunotherapy. The uveitis and scleritis resolved following temporary discontinuation of nivolumab and cabiralizumab as well as systemic prednisone.

Conclusions and importance: Ophthalmologists should be aware of the possibility of acute ocular inflammation developing with cancer immunotherapy. Systemic corticosteroids play a first-line role in managing such immune-mediated side effects.

Keywords: Cabiralizumab; Cancer immunotherapy; Nivolumab; Scleritis; Side effects; Uveitis.

Abstract

Grants and funding